Profund Advisors Llc decreased its stake in Amgen Inc (AMGN) by 4.42% based on its latest 2016Q3 regulatory filing with the SEC. Profund Advisors Llc sold 19,888 shares as the company’s stock rose 8.12% with the market. The institutional investor held 429,952 shares of the biological products (no diagnostic substances) company at the end of 2016Q3, valued at $71.72M, down from 449,840 at the end of the previous reported quarter. Profund Advisors Llc who had been investing in Amgen Inc for a number of months, seems to be less bullish one the $119.66B market cap company. The stock decreased 0.05% or $0.08 during the last trading session, hitting $158.76. Amgen, Inc. (NASDAQ:AMGN) has declined 0.08% since June 7, 2016 and is downtrending. It has underperformed by 7.50% the S&P500.
Profund Advisors Llc, which manages about $4.85B and $2.10B US Long portfolio, upped its stake in Facebook Inc (NASDAQ:FB) by 33,069 shares to 242,724 shares, valued at $31.13M in 2016Q3, according to the filing. It also increased its holding in Texas Instrs Inc (NASDAQ:TXN) by 111,791 shares in the quarter, for a total of 199,453 shares, and has risen its stake in Alibaba Group Hldg Ltd (NYSE:BABA).
Profund Advisors Llc is a Maryland-based institutional investor with more than $4.85 billion AUM in March, 2014. Taken from Profund Advisors latest Adv, the fund reported to have 87 full and part-time employees. Among which 42 performing investment advisory and research functions. The institutional investor had more than 200 clients.
Insitutional Activity: The institutional sentiment decreased to 1.26 in Q3 2016. Its down 0.02, from 1.28 in 2016Q2. The ratio dropped, as 46 funds sold all AMGN shares owned while 474 reduced positions. 134 funds bought stakes while 523 increased positions. They now own 568.98 million shares or 1.53% less from 577.82 million shares in 2016Q2. Reilly Financial Advisors Limited Co has 2,652 shares for 0.08% of their US portfolio. Robecosam Ag has invested 0.42% of its portfolio in Amgen, Inc. (NASDAQ:AMGN). Natixis has 20,106 shares for 0.04% of their US portfolio. Bogle Mngmt Lp De has invested 0.79% of its portfolio in Amgen, Inc. (NASDAQ:AMGN). Spc last reported 8,970 shares in the company. Burns J W And accumulated 0.51% or 9,978 shares. Artemis Investment Management Llp accumulated 191,155 shares or 0.89% of the stock. Cohen Klingenstein Limited Com holds 33,020 shares or 0.96% of its portfolio. First City Cap Mngmt, a Georgia-based fund reported 4,020 shares. Community Tru And Investment accumulated 0.04% or 1,669 shares. Papp L Roy & Associate holds 0.37% of its portfolio in Amgen, Inc. (NASDAQ:AMGN) for 9,679 shares. Forte Lc Adv reported 14,388 shares or 0.91% of all its holdings. First Long Island Investors Limited Company has 2.71% invested in the company for 89,629 shares. The Connecticut-based Sustainable Growth Advisers Ltd Partnership has invested 3.76% in Amgen, Inc. (NASDAQ:AMGN). The California-based Schnieders Cap Mgmt Ltd Liability has invested 1.79% in Amgen, Inc. (NASDAQ:AMGN).
Insider Transactions: Since August 1, 2016, the stock had 0 buys, and 1 sale for $523,758 net activity. Such Annette Louise had sold 3,000 shares worth $523,758.
Analysts await Amgen, Inc. (NASDAQ:AMGN) to report earnings on January, 26. They expect $2.77 earnings per share, up 6.13% or $0.16 from last year’s $2.61 per share. AMGN’s profit will be $2.09 billion for 14.33 P/E if the $2.77 EPS becomes a reality. After $3.02 actual earnings per share reported by Amgen, Inc. for the previous quarter, Wall Street now forecasts -8.28% negative EPS growth.
More notable recent Amgen, Inc. (NASDAQ:AMGN) news were published by: Seekingalpha.com which released: “Amgen Should Drop At Least 10% To 15%” on January 10, 2017, also Bloomberg.com with their article: “Amgen Wins Ban on Sanofi’s Praluent Cholesterol Drug Sales” published on January 05, 2017, Fool.com published: “Better Buy: Gilead Sciences Inc. vs. Amgen Inc.” on December 13, 2016. More interesting news about Amgen, Inc. (NASDAQ:AMGN) were released by: Zacks.com and their article: “Amgen Inks Multiple Deals, Offers Update on Repatha Lawsuit” published on January 10, 2017 as well as Investorplace.com‘s news article titled: “Amgen, Inc. (AMGN) Stock Might Be on Santa’s Buy List” with publication date: December 12, 2016.
According to Zacks Investment Research, “Amgen Inc. discovers, develops and delivers innovative human therapeutics. A biotechnology pioneer, Amgen was one of the first companies to realize the new science’s promise by bringing safe and effective medicines from lab, to manufacturing plant, to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people’s lives.”
Amgen, Inc. (NASDAQ:AMGN) Ratings Coverage
Out of 18 analysts covering Amgen Inc. (NASDAQ:AMGN), 10 rate it a “Buy”, 0 “Sell”, while 8 “Hold”. This means 56% are positive. $218 is the highest target while $160 is the lowest. The $187.39 average target is 18.03% above today’s ($158.76) stock price. Amgen Inc. has been the topic of 31 analyst reports since August 3, 2015 according to StockzIntelligence Inc. The firm has “Market Perform” rating given on Wednesday, June 29 by Bernstein. The company was downgraded on Tuesday, December 20 by Credit Suisse. The rating was initiated by Raymond James on Tuesday, September 1 with “Market Perform”. The stock has “Overweight” rating given by Atlantic Securities on Friday, December 18. The firm earned “Overweight” rating on Tuesday, December 15 by Morgan Stanley. UBS maintained the stock with “Buy” rating in Thursday, October 29 report. The stock of Amgen, Inc. (NASDAQ:AMGN) earned “Buy” rating by Mizuho on Tuesday, November 8. Citigroup maintained Amgen, Inc. (NASDAQ:AMGN) rating on Friday, July 29. Citigroup has “Neutral” rating and $175 price target. On Friday, December 4 the stock rating was initiated by Wells Fargo with “Market Perform”. The rating was upgraded by Vetr to “Buy” on Friday, August 21.
AMGN Company Profile
Amgen Inc., incorporated on October 31, 1986, is a biotechnology company. The Firm discovers, develops, makes and delivers various human therapeutics. The Company’s business segment is human therapeutics. The Company’s marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as Vectibix (panitumumab), Nplate (romiplostim) and Corlanor (ivabradine). The Firm focuses its research and development on human therapeutics for the treatment of serious illness in the areas of oncology/hematology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.